Biotech and Pharmaceuticals Life Sciences

More

  • LONDON— Pharmaceutical company GlaxoSmithKline says higher sales of vaccines and consumer healthcare products pushed up its earnings from core business by 19 percent in the first quarter. Core operating profit, which excludes taxes, one-time items and restructuring costs, rose to 1.56 billion pounds from 1.31 billion pounds in the same quarter a year...

  • Sandy & Joan Weill's $185M gift to neuroscience

    Sandy Weill, Citigroup chairman emeritus and former CEO, and his wife Joan discuss their $185 million gift to the University of California, San Francisco for neuroscience research. They believe that this is the decade that neuroscience catches up to other progress in similar sciences. Sandy Weill also weighs in on the financial sector and the prospects for Citigroup.

  • A three-toed sloth from Costa Rica

    Scientists say humans have changed the world so dramatically that the planet's biodiversity is on the decline.

  • April 5- The U.S. Food and Drug Administration on Tuesday approved Inflectra, a cheaper version of Johnson& Johnson's drug Remicade, to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis and arthritis of the spine. Inflectra, made by South Korea's Celltrion Inc and Pfizer Inc's Hospira unit, was the second biosimilar approved by the FDA.

  • Crossfit CEO: We're a threat to the industry, not people's wellbeing

    Greg Glassman, Crossfit Founder & CEO, talks about his fitness revolution at the iCONIC Conference in Seattle.

  • How sleeps improves our productivity: Aetna CEO

    Mark Bertolini, Aetna CEO & chairman, discusses how his company is getting employees to improve their sleep, thus improving the company's bottom line. And Bertolini shares his thoughts on Obamacare.

  • LONDON, April 1- The world's first life-saving gene therapy for children, developed by Italian scientists and GlaxoSmithKline, has been recommended for approval in Europe, boosting the pioneering technology to fix faulty genes. Around 15 children a year are born in Europe with the ultra-rare genetic disorder, which leaves them unable to make a type of white...

  • BRIEF-GLAXOSMITHKLINE SAYS GENE THERAPY FOR IMMUNODEFICIENCY. GETS POSITIVE CHMP RECOMMENDATION@ CHMP recommendation@. *Gsk receives positive CHMP opinion for Strimvelis.

  • April 1- Array BioPharma Inc said it was abandoning a late-stage study testing its experimental ovarian cancer drug, after an interim analysis showed the trial would likely fail. The biotechnology company regained the rights to the compound from Novartis AG in March 2015, five years after licensing it to the Swiss drugmaker. Boulder, Colorado- based Array's...

  • IBM's 'Watson' lends Guiding Eyes a paw

    Thomas Panek, Guiding Eyes president & CEO, discusses his organization's partnership with IBM as they attempt to analyze and collect data about its dogs in an effort to perfect the breeding and training process.

  • The test, manufactured by a New Jersey- based unit of Swiss drugmaker Roche Holding AG, may be used for screening donated blood in areas with active mosquito-borne transmission of Zika virus, the FDA said. At the time, the FDA also urged that areas with active Zika transmission fulfill blood orders from areas where the virus is not circulating, except when the blood...

  • LONDON, March 29- French drugmaker Sanofi has poached one of AstraZeneca's top scientists to be its new research head in another high-profile departure for the British drugmaker. Sanofi said on Tuesday that Yong-Jun Liu had been appointed as head of research with effect from April 1, reporting to Elias Zerhouni, the group's president of global research and...

  • LONDON, March 29- Lower-cost copies of complex biotech drugs, known as biosimilars, could save the United States and Europe's five top markets as much as 98 billion euros by 2020, a new analysis showed on Tuesday. The IMS forecast covers Germany, France, Italy, Britain, Spain and the United States. IMS said Germany had been particularly successful in stimulating...

  • BRIEF-GSK AND MILTENYI BIOTEC ESTABLISH CELL AND GENE THERAPY. *GSK and Miltenyi Biotec today announced a strategic collaboration that will bring together GSK's expertise in developing cell and gene therapy based treatments with Miltenyi Biotec's global leadership in cell processing. *Collaboration seeks to optimize manufacture& delivery of...

  • The digital and real world are blending: Dr. Michael Wu

    Dr. Michael Wu, chief scientist at Lithium Technologies, discusses technology trends from CeBIT in Germany.

  • Some of the world's poorest countries and medical charities such as Medecins Sans Frontieres depend on India's robust pharmaceutical industry to make cheaper forms of drugs and vaccines developed by big Western pharmaceutical companies such as Pfizer. If India granted Pfizer a patent on its Prevnar 13 pneumonia vaccine, Indian firms would not be able to...

  • March 7- The U.S. Department of Health and Human Services said it was arranging and funding shipments of blood products to Puerto Rico to ensure an adequate supply of safe blood as the U.S. territory struggles with an outbreak of the mosquito-borne Zika virus. The shipments are being provided to Puerto Rico through the American Red Cross, the Blood Centers of...

  • LONDON, March 3- French drugmaker Sanofi has slammed its foot on the gas since announcing the launch of Zika vaccine programme a month ago. Nicholas Jackson, who heads up the effort, said on Thursday he had now assembled a team of more than 80 in-house experts who would start preclinical tests of a potential vaccine in animals this spring. Sanofi is chasing rivals...

  • March 1- The U.S. Food and Drug Administration on Tuesday issued new recommendations aimed at reducing the risk of Zika virus transmission through donated human tissues and cells used in surgical or reproductive procedures, such as umbilical cord blood, corneas and heart valves. The guidance is part of the agency's ongoing efforts to protect human cellular,...

  • NEW YORK, Feb 26- Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. The Knoxville, Tennessee, company reported promising results in a small melanoma study. The company must replicate its early results on a bigger scale, and a U.S. Food and Drug Administration decision is not expected before...